Study guide
13.2 Cardiac Function, Viability, and Special Studies
Certified Nuclear Medicine Technologist CNMT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CNMT Exam Facts 1.2 How to Use This Guide
2 Radiation Physics Fundamentals
2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles
3 Biological Effects & ALARA
3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring
4 NRC & Regulatory Compliance
4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records
5 Generators & Kit Preparation
5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control
6 Tc-99m Diagnostic Agents
6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells
7 Non-Tc Diagnostic & PET Agents
7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents
8 Therapeutics, Adjuncts & Administration
8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents
9 Non-Imaging Instrumentation
9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment
10 Imaging Systems & Quality Control
10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization
11 Pulmonary, Bone, Oncology & Infection Imaging
11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures
12 Renal, Endocrine & Hematopoietic Imaging
12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique
13 Cardiovascular Procedures
13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing
14 GI, CNS, Therapy & Hybrid CT Procedures
14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
15 Patient Care & Clinical Workflow
15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis
13.2 Cardiac Function, Viability, and Special Studies
Key Takeaways Explain This Topic AI
First-pass radionuclide angiography measures right and left ventricular EF and wall motion from a tight IV bolus; MUGA (ERNA) uses labeled RBCs for high-precision LVEF at rest (± stress) and SPECT blood-pool options
Cardiac shunt quantification compares systemic vs pulmonary flow using first-pass curves when ordered
Tc-99m PYP planar + SPECT for ATTR cardiac amyloidosis: image ~1 h and/or 3 h; semi-quantitative visual grades and H/CL (heart-to-contralateral lung) ratio concepts support interpretation
Cardiac sarcoidosis evaluation favors FDG PET with strict dietary/prep protocols; I-123 MIBG assesses cardiac sympathetic innervation
Viability: Tl-201 rest–redistribution (or stress-redistribution-reinjection pathways) vs FDG PET metabolic imaging after glucose loading/insulin euglycemia prep
Last updated: August 2026
13.2 Cardiac Function, Viability, and Special Studies
Quick Answer: First-pass = bolus EF/wall motion (RV & LV). MUGA/ERNA = Tc-99m labeled RBCs , high-precision serial LVEF . Shunt studies use first-pass curve analysis. PYP = ATTR amyloid (1 h / 3 h, visual grade, H/CL ). FDG PET = sarcoid (prep!) and viability . MIBG = innervation. Tl-201 rest-redistribution or FDG for viability when revascularization is considered.
Order these studies for function , infiltrate/inflammation , innervation , or hibernating myocardium —not routine CAD screening alone.
First-Pass Radionuclide Angiography
A compact IV bolus (often Tc-99m DTPA, pertechnetate, or lab-chosen first-pass agent) is imaged with rapid frames as activity traverses SVC → RV → lungs → LV → aorta.
- Output Teaching value
- RVEF / LVEF Count-based ejection fractions from time-activity curves
- Wall motion Regional qualitative assessment during transit
- Shunt clues Abnormal recirculation patterns
Tech keys: large vein, bolus integrity (no infiltrate, rapid flush), high frame rate, correct ROIs. A fragmented bolus invalidates quantitative EF.
Gated Blood Pool (MUGA / ERNA)
Equilibrium radionuclide angiocardiography (ERNA/MUGA) uses Tc-99m labeled autologous RBCs (in vivo, modified in vivo, or in vitro). After mixing, ECG-gated planar images (classic best septal LAO for EF) sum many beats into one representative cycle.
- Setting Notes
- Rest MUGA Serial LVEF (e.g., chemotherapy cardiotoxicity)
- Stress MUGA Exercise or pharmacologic stress with gating
- SPECT blood pool Tomographic volumes/wall motion
- Typical activity Often ~20–30 mCi Tc-99m RBCs
Why MUGA endures: excellent LVEF reproducibility when labeling and ROI methods stay consistent. QC includes labeling efficiency, arrhythmia rejection, count density, and background ROI. Highly irregular AF degrades frames—document and apply lab filters.
Labeling pitfalls matter: poor RBC tag leaves free Tc-99m (stomach, thyroid, soft tissue) and undercuts chamber contrast. Verify the labeling method on the order (in vitro kits often give higher efficiency) and image only after adequate equilibration.
Cardiac Shunt Evaluation
Left-to-right shunts alter pulmonary transit on first-pass curves; quantitative methods estimate Qp/Qs . Right-to-left shunts may use Tc-99m MAA (systemic foci after venous injection). Match agent and analysis to the ordered shunt direction.
Cardiac Amyloidosis: Tc-99m PYP
ATTR cardiac amyloid is often Tc-99m PYP -avid; AL is less so—labs combine imaging with monoclonal protein workups. Technologists still must execute timing and SPECT correctly.
- Protocol element Teaching practice
- Activity Often ~10–25 mCi Tc-99m PYP IV
- Imaging times ~1 hour and/or ~3 hours planar + SPECT/SPECT-CT
- Visual grading Heart vs rib (0–3 style; grade ≥2 at 3 h supports ATTR pattern when criteria met)
H/CL ratio Heart / contralateral lung counts; elevated ratio (classic teaching near ~1.5 at 1 h—use lab cutoffs) supports abnormal retention
SPECT role Confirms myocardial, not blood-pool, uptake
Note recent MI (classic infarct-avid use of PYP) and keep ROIs consistent.
Planar-only reading can mistake blood-pool activity for myocardial uptake—SPECT (or SPECT/CT) is required to localize tracer to myocardium. Time both 1 h and 3 h sets the same way each visit so visual grades and H/CL ratios remain comparable.
Cardiac Sarcoidosis PET
F-18 FDG PET/CT (± perfusion imaging) detects active myocardial inflammation. Prep is strict and lab-specific: prolonged high-fat, low-carbohydrate diet , fasting, sometimes heparin , to suppress normal myocyte glucose uptake . Failed prep → diffuse physiologic FDG that mimics or masks disease. This is not a casual oncology FDG instruction set.
Cardiac MIBG
I-123 MIBG maps sympathetic innervation (heart-to-mediastinum ratios, washout). Hold interfering drugs per lab list; follow iodine thyroid-protection rules when applicable. MIBG is not a substitute for MPI ischemia mapping.
Myocardial Viability
Approach Concept When chosen
Tl-201 rest–redistribution Rest uptake + 3–4 h (sometimes 24 h) fill-in = viable hibernation SPECT viability without FDG
Tl-201 stress–redistribution ± reinjection Stress defect with later uptake Combined ischemia + viability
F-18 FDG viability PET FDG-avid tissue in a perfusion defect = mismatch (hibernating); matched severe reduction = scar Metabolic gold standard when available
Tc-99m rest uptake (supportive) Preserved rest perfusion favors viability Adjunct, less definitive
FDG viability prep uses glucose loading/insulin euglycemia to stimulate myocyte FDG uptake—the opposite goal of sarcoid suppression prep. Swapping those preps is a classic board trap.
When reporting viability language at the tech level, remember: perfusion-metabolism mismatch suggests hibernating myocardium that may improve after revascularization; matched severe reduction suggests scar with less recovery potential. Actual revascularization decisions remain clinical.
Choosing the Study
- Clinical question Nuclear package
- Serial LVEF on cardiotoxic chemo Rest MUGA
- RV function / shunt / bolus EF First-pass
- ATTR amyloid Tc-99m PYP 1 h/3 h + SPECT, H/CL
- Cardiac sarcoid inflammation FDG PET with suppression prep
- Sympathetic denervation I-123 MIBG
- Hibernation before revascularization Tl-201 redistribution and/or FDG viability
- Daily CAD ischemia vs scar MPI (± gating) first (§13.1)
Bottom line: name the question , pick the agent and prep , and defend bolus quality, labeling, timing, and ratios .